[PDF][PDF] Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
ML Rothenberg, B LaFleur, DE Levy… - Journal of Clinical …, 2005 - Citeseer
ML Rothenberg, B LaFleur, DE Levy, MK Washington, SL Morgan-Meadows…
Journal of Clinical Oncology, 2005•CiteseerPurpose The clinical objective of this trial was to evaluate gefitinib in patients with metastatic
colorectal cancer that had progressed despite prior treatment. Serial tumor biopsies were
performed when possible and analyzed for activation of the epidermal growth factor receptor
(EGFR) signaling pathway. Serial serum samples were measured for amphiregulin and
transforming growth factor–alpha (TGF).
colorectal cancer that had progressed despite prior treatment. Serial tumor biopsies were
performed when possible and analyzed for activation of the epidermal growth factor receptor
(EGFR) signaling pathway. Serial serum samples were measured for amphiregulin and
transforming growth factor–alpha (TGF).
Purpose
The clinical objective of this trial was to evaluate gefitinib in patients with metastatic colorectal cancer that had progressed despite prior treatment. Serial tumor biopsies were performed when possible and analyzed for activation of the epidermal growth factor receptor (EGFR) signaling pathway. Serial serum samples were measured for amphiregulin and transforming growth factor–alpha (TGF).
Citeseer